Is hepatocellular carcinoma complicated with portal vein tumor thrombosis potentially curable by radiotherapy in the form of stereotactic body radiation therapy?-Reference-Cited by-同舟云学术

Is hepatocellular carcinoma complicated with portal vein tumor thrombosis potentially curable by radiotherapy in the form of stereotactic body radiation therapy?

Published:2022-04-04 Issue:10 Volume:98 Page:1495-1509
ISSN:0955-3002
Container-title:International Journal of Radiation Biology
language:en
Short-container-title:International Journal of Radiation Biology

Author:

Srivastava Astha¹,Parambath Haresh Kunhi¹,Ramdulari Anjali V.¹,Saxena Harsh²,Kumar Rishabh¹,Pandey Suyash¹,Shalimar ³,Gupta Subhash¹,Jee Babban⁴^ORCID

Affiliation:

1. Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India

2. Department of Medicine Trauma, All India Institute of Medical Sciences, New Delhi, India

3. Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India

4. Department of Health Research, Ministry of Health and Family Welfare, Government of India, New Delhi, India

Funder

Department of Health Research, Ministry of Health and Family Welfare, Government of India

Publisher

Informa UK Limited

Subject

Radiology, Nuclear Medicine and imaging,Radiological and Ultrasound Technology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09553002.2022.2055800

Reference127 articles.

1. SBRT for Hepatocellular Carcinoma With Portal Vein Invasion From Palliation to a Cure

2. Stereotactic Body Radiotherapy for Primary Hepatocellular Carcinoma

3. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017

4. Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis

5. The determinants of tumour immunogenicity

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2023 Update of Indian National Association for Study of the Liver Consensus on Management of Intermediate and Advanced Hepatocellular Carcinoma: The Puri III Recommendations;Journal of Clinical and Experimental Hepatology;2024-01